Namibia Pharmaceuticals and Healthcare Report Q4 2017
After reporting negative growth since Q216, the Namibian economy likely bottomed in H117and will begin to rebound in the coming quarters. However, the country's relatively small pharmaceuticalmarket and below-average per capita spending on medicines lower the country's competitiveness in theSouthern Africa region. These factors continue to act as a deterrent to multinational pharmaceuticalcompany investment in the local production of medicines.
Headline Expenditure Forecasts
Pharmaceuticals: NAD2.54bn (USD173mn) in 2016 to NAD2.76bn (USD212mn) in 2017; +8.7% inlocal currency and 22.6% in US dollar terms. Forecast unchanged compared to last quarter.
Healthcare: NAD15.7bn (USD1.07bn) in 2016 to NAD17.2bn (USD1.32bn) in 2017; +9.7% in localcurrency and 23.8% in US dollar terms. Forecast unchanged compared to last quarter.